Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431710 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2HPGDNPSR1HTT | |
| SCHEMBL2434531 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2HPGDNPSR1HTT | |
| SCHEMBL2434526 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2HPGDNPSR1HTT | |
| SCHEMBL4845297 | 0.86 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HPGDNPSR1HTT | |
| SCHEMBL2431591 | 0.86 | KMT2A (0.37) | ALDH1A1SMN1; SMN2NPSR1HTTKMT2A | |
| SCHEMBL4845307 | 0.86 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HPGDNPSR1HTT | |
| SCHEMBL2431589 | 0.86 | KMT2A (0.37) | ALDH1A1SMN1; SMN2NPSR1HTTKMT2A | |
| SCHEMBL17244346 | 0.86 | LMNA (0.35) | ALDH1A1HPGDNPSR1HTTKMT2A | |
| SCHEMBL6103454 | 0.83 | ALDH1A1 (0.33) | ALDH1A1HPGDKMT2AMEN1L3MBTL1 | |
| SCHEMBL2435345 | 0.83 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2HPGDNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| EP-2086966-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SmithKline Beecham Corporation (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008125599-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | ALDH1A1 860/4885SMN1; SMN2 1772/4885HPGD 4541/4885 |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | ALDH1A1 1037/4885SMN1; SMN2 1628/4885HPGD 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.